Phase III Study of AK112 for NSCLC Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
74 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Bc Cancer
Vancouver, British Columbia, Canada
- Lung Cancer Canada
Ottawa, Ontario, Canada
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Allan Blaire Cancer Centre
Regina, Saskatchewan, Canada
- Universite Hospital Laval
Québec, Canada
- Chi Creteil
Créteil, France
- Léon Bérard Cancer Center, Lyon
Lyon, France
- Hospital Bichat-Claude Bernard
Paris, France
- Institut Curie
Paris, France
- Gustave Roussy Cancer
Villejuif, France
- Instituto Europeo Di Oncologia
Milan, Italy
- Istituto Nazionale Dei Tumori
Milan, Italy
- University Hospital of Parma
Parma, Italy
- Campus Bio-Medico University
Roma, Italy
- Istituto Nazionale Tumori, Regina Elena
Rome, Italy
- Hospital Teresa Herrera
A Coruña, Spain
- Badalona-Hospital Germans Trias I Pujol
Barcelona, Spain
- Vall D'Hebron Institute of Oncology
Barcelona, Spain
- Omplejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria
Las Palmas, Spain
- Lucus Augusti University Hospital
Lugo, Spain
- Hospital General Universitario Gregorio Maranon
Madrid, Spain
- Hospital Universitario Clinico San Carlos
Madrid, Spain
- Hospital Universitario la Paz
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz
Madrid, Spain
- Puerta de Hierro University Hospital
Majadahonda, Spain
- Hospital Regional Universitario de Malaga
Málaga, Spain
- Hospital Universitario Nuestro Senora de Valme
Seville, Spain
- the Royal Marsden
London, United Kingdom
- the Christie Nhs Foundation Trust
Manchester, United Kingdom
- Cbcc Global Research
Bakersfield, California, United States
- Uc San Diego
La Jolla, California, United States
- Ucla Department of Medicine - Hematology/oncology
Los Angeles, California, United States
- University of Southern California
Los Angeles, California, United States
- Valkyrie Clinical Trials
Los Angeles, California, United States
- Palo Alto Medical Foundation Research Institute
Mountain View, California, United States
- Providence St. Joseph
Orange, California, United States
- Uc Irvine
Orange, California, United States
- Sutter Cancer Center
Sacramento, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 May 2023
- Primary completion
- 12 Apr 2025
- Completion
- 31 Dec 2026
- Last update posted
- 24 Mar 2026
- Registered enrollment
- 420
- Registry id
- NCT06396065
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.